AC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease ...
AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...
Cheshire Live on MSN5h
Cheshire boxing gym 'delighted' to offer UK firstA Cheshire-based boxing gym said it is "delighted" to be welcoming a UK first to its venues. Rock Steady Boxing, which has ...
Nightmares can be caused by a range of conditions from Parkinson's to sleep apnoea - and they can even help diagnose your ...
A team of Tel Aviv University researchers claims to have made progress in the path to treating Parkinson’s disease. The team found that a variant of a protein, caused by a genetic mutation, enhances ...
A breakthrough in the fight against Alzheimer’s disease may have been made in Seattle. Researchers at the Allen Institute ...
The weight-loss jab Wegovy made its debut on June 4 2021 . It was the first new weight-loss drug to be approved by the US ...
Researchers have developed a simple model system that can be used to break down fibrils -- the cause of numerous disorders including Alzheimer's and Parkinson's disease -- into their constituent ...
Researchers are using functionalized nanodiamonds to precisely monitor neuronal activity at the cellular level, enhancing ...
The interim phase 2 trial results show a good immune response in participants and the therapy is well tolerated to date.
Could your dreams be trying to tell you something? Discover the surprising connections between what haunts you at night and ...
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s DiseaseActive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback